140 related articles for article (PubMed ID: 33082322)
41. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
[TBL] [Abstract][Full Text] [Related]
42. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
43. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
44. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
45. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
46. Requirement of GSK-3 for PUMA induction upon loss of pro-survival PI3K signaling.
Schubert F; Rapp J; Brauns-Schubert P; Schlicher L; Stock K; Wissler M; Weiß M; Charvet C; Borner C; Maurer U
Cell Death Dis; 2018 May; 9(5):470. PubMed ID: 29686375
[TBL] [Abstract][Full Text] [Related]
47. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
48. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
49. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
Guirguis AA; Slape CI; Failla LM; Saw J; Tremblay CS; Powell DR; Rossello F; Wei A; Strasser A; Curtis DJ
Cell Death Differ; 2016 Jun; 23(6):1049-59. PubMed ID: 26742432
[TBL] [Abstract][Full Text] [Related]
50. Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.
Nie P; Hu W; Zhang T; Yang Y; Hou B; Zou Z
Cell Physiol Biochem; 2015; 35(6):2255-71. PubMed ID: 25895606
[TBL] [Abstract][Full Text] [Related]
51. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
[TBL] [Abstract][Full Text] [Related]
52. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Dong S; Kang S; Gu TL; Kardar S; Fu H; Lonial S; Khoury HJ; Khuri F; Chen J
Blood; 2007 Jul; 110(1):360-9. PubMed ID: 17389761
[TBL] [Abstract][Full Text] [Related]
53. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
54. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
[TBL] [Abstract][Full Text] [Related]
55. Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.
Dey P; Ström A; Gustafsson JÅ
Oncogene; 2014 Aug; 33(33):4213-25. PubMed ID: 24077289
[TBL] [Abstract][Full Text] [Related]
56. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
Liang D; Chen Q; Guo Y; Zhang T; Guo W
Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
[TBL] [Abstract][Full Text] [Related]
57. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.
Verstovsek S; Subbiah V; Masarova L; Yin CC; Tang G; Manshouri T; Asatiani E; Daver NG
Ann Oncol; 2018 Aug; 29(8):1880-1882. PubMed ID: 29767670
[No Abstract] [Full Text] [Related]
58. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
59. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
60. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming.
Zhang ZJ; Wu QF; Ren AQ; Chen Q; Shi JZ; Li JP; Liu XY; Zhang ZJ; Tang YZ; Zhao Y; Yao NN; Zhang XY; Liu CP; Dong G; Zhao JX; Xu MJ; Yue YQ; Hu J; Sun F; Liu Y; Ao QL; Zhou FL; Wu H; Zhang TC; Zhu HC
Acta Pharmacol Sin; 2023 Nov; 44(11):2282-2295. PubMed ID: 37280363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]